Spanish Scientists Achieve Breakthrough in Pancreatic Cancer Research
A Historic Preclinical Milestone
In a groundbreaking preclinical study, Spanish scientists led by Dr. Mariano Barbacid at the National Cancer Research Center (CNIO) have successfully eradicated pancreatic ductal adenocarcinoma (PDAC) tumors in rat and mouse models. Published in the Proceedings of the National Academy of Sciences (PNAS), this research addresses one of the deadliest cancers, driven in roughly 95% of cases by mutations in the KRAS oncogene. The results mark the first time complete and sustained tumor regression has been observed in such advanced preclinical models.
Triple-Inhibitor Therapy Targets Key Pathways
The innovative treatment combines three approaches designed to prevent tumor adaptation: MEK inhibition through trametinib, suppression of anti-apoptotic proteins BCL2/XL via navitoclax, and a novel EGFR degrader that blocks tumor escape mechanisms. By simultaneously targeting multiple KRAS dependent pathways, the therapy avoids the common problem of resistance seen in previous single-drug approaches. The outcome was remarkable, tumors completely disappeared, with no recurrences, relapses, or significant side effects.
Insights from Dr. Barbacid
In an interview with elEconomista.es, Dr. Barbacid emphasized the importance of attacking multiple pathways simultaneously. He explained that this strategy prevents cancer cells from adapting and evading treatment. Dressed in his lab coat, he described how the tumors vanished entirely and underscored that the results demonstrate the feasibility of durable preclinical responses in pancreatic cancer, a malignancy long resistant to therapy.
The Role of Fundación CRIS Against Cancer
The study was supported by Fundación CRIS Contra el Cancer, highlighting the vital role of private funding in high-risk, innovative cancer research. Dr. Barbacid stressed that sustained investment in research is critical for progress. “If there is no research, there is no progress,” he stated, emphasizing that breakthroughs like this are the product of long-term commitment and collaboration.
Implications for Future Therapy
While human clinical trials have not yet begun, this research lays a promising foundation for new therapeutic strategies. The findings suggest a potential path to overcoming the resistance mechanisms that have limited the effectiveness of KRAS-targeted therapies in humans. Given PDAC’s notoriously low five-year survival rate of around 13%, these results provide a significant beacon of hope for patients and researchers alike.
Looking Ahead
This achievement not only advances our understanding of pancreatic cancer biology but also reinforces the importance of precision, multi-targeted strategies in oncology. By attacking the disease from multiple angles, scientists can potentially develop safer, more effective treatments. As research continues, the lessons learned from these preclinical models may ultimately inform human therapies and offer a path toward lasting remission for one of the most lethal cancers.
Watch the video of Dr. Mariano Barbacid explaining the findings here:
